Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke

Neurology

Volumn 82, Issue 14, 2014, Pages 1277-1286

  Vu, Quynh ^a   Xie, Kate ^a   Eckert, Mark ^a   Zhao, Weian ^a   Cramer, Steven C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIVE REMOVAL TEST; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; HUMAN; IMMUNOGENICITY; MESENCHYMAL STROMA CELL; META ANALYSIS; NEUROLOGICAL SEVERITY SCORE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; ROTAROD TEST; SCORING SYSTEM; TREATMENT OUTCOME;

ANIMALS; BRAIN ISCHEMIA; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; OUTCOME ASSESSMENT (HEALTH CARE); RATS; RECOVERY OF FUNCTION; STROKE;

EID: 84902207525     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000278     Document Type: Review

References (57)

1. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952-1955.
2. Cramer SC, Stradling D, Brown DM, et al. Organization of a United States county system for comprehensive acute stroke care. Stroke 2012;43:1089-1093.
3. Cramer SC. Repairing the human brain after stroke: II: restorative therapies. Ann Neurol 2008;63:549-560.
4. Janowski M, Walczak P, Date I. Intravenous route of cell delivery for treatment of neurological disorders: a metaanalysis of preclinical results. Stem Cells Dev 2010;19: 5-16.
5. Lees JS, Sena ES, Egan KJ, et al. Stem cell-based therapy for experimental stroke: a systematic review and metaanalysis. Int J Stroke 2012;7:582-588.
6. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
7. Li Y, Chopp M. Marrow stromal cell transplantation in stroke and traumatic brain injury. Neurosci Lett 2009; 456:120-123.
8. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007;25:2896-2902.
9. Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive properties of mesenchymal stem cells. Stem Cell Rev 2012;8:375-392.
10. Chagastelles PC, Nardi NB, Camassola M. Biology and applications of mesenchymal stem cells. Sci Prog 2010;93: 113-127.
11. Honmou O, Onodera R, Sasaki M, Waxman SG, Kocsis JD. Mesenchymal stem cells: therapeutic outlook for stroke. Trends Mol Med 2012;18:292-297.
12. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011;109: 923-940.
13. Figueroa FE, Carrion F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res 2012;45:269-277.
14. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (Safe Cell): a systematic review and meta-analysis of clinical trials. PloS One 2012;7:e47559.
15. Dharmasaroja P. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J Clin Neurosci 2009;16:12-20.
16. Fisher M, Feuerstein G, Howells DW, et al. Update of the Stroke Therapy Academic Industry Roundtable preclinical recommendations. Stroke 2009;40:2244-2250.
17. Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012;490:187-191.
18. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-477.
19. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 2005;25:713-721.
20. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008;39:2824-2829.
21. Crossley NA, Sena E, Goehler J, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 2008;39:929-934.
22. Jerndal M, Forsberg K, Sena ES, et al. A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab 2010;30:961-968.
23. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
24. Durlak JA. How to select, calculate, and interpret effect sizes. J Pediatr Psychol 2009;34:917-928.
25. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration, 2011 [online]. Available at: http://www.cochrane-handbook.org. Accessed March 2011.
26. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
27. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
28. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Psychology Press; 1988.
29. Marchal G, Beaudouin V, Rioux P, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxelbased data analysis. Stroke 1996;27:599-606.
30. Kolb B, Morshead C, Gonzalez C, et al. Growth factorstimulated generation of new cortical tissue and functional recovery after stroke damage to the motor cortex of rats. J Cereb Blood Flow Metab 2007;27:983-997.
31. Bacigaluppi M, Pluchino S, Jametti LP, et al. Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain 2009;132:2239-2251.
32. Guadagno JV, Jones PS, Aigbirhio FI, et al. Selective neuronal loss in rescued penumbra relates to initial hypoperfusion. Brain 2008;131:2666-2678.
33. Ren J, Kaplan P, Charette M, Speller H, Finklestein S. Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke. Neuropharmacology 2000;39:860-865.
34. Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci 2004;24:1245-1254.
35. Adams HP Jr, Robinson RG. Improving recovery after stroke: a role for antidepressant medications? Stroke 2012;43:2829-2832.
36. Saver JL, Smith EE, Fonarow GC, et al. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in 30,000 patients arriving within 60 minutes of stroke onset. Stroke 2010;41:1431-1439.
37. Naaldijk Y, Staude M, Fedorova V, Stolzing A. Effect of different freezing rates during cryopreservation of rat mesenchymal stem cells using combinations of hydroxyethyl starch and dimethylsulfoxide. BMC Biotechnol 2012;12:49.
38. Whiteside TL, Griffin DL, Stanson J, et al. Shipping of therapeutic somatic cell products. Cytotherapy 2011;13: 201-213.
39. Lane T, Garls D, Mackintosh E, Kohli S, Cramer S. Liquid storage of marrow stromal cells. Transfusion 2009;49: 1471-1481.
40. Lu SS, Liu S, Zu QQ, et al. In vivo MR imaging of intraarterially delivered magnetically labeled mesenchymal stem cells in a canine stroke model. PloS One 2013;8: e54963.
41. Sole A, Spriet M, Padgett KA, et al. Distribution and persistence of technetium-99 hexamethyl propylene amine oxime-labelled bone marrow-derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb. Equine Vet J 2013;45:726-731.
42. Toma C, Wagner WR, Bowry S, Schwartz A, Villanueva F. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ Res 2009;104:398-402.
43. Feeney D, Gonzalez A, Law W. Amphetamine, haloperidol, and experience interact to affect the rate of recovery after motor cortex injury. Science 1982;217:855-857.
44. Cramer SC. Issues in clinical trial methodology for brain repair after stroke. In: Cramer SC, Nudo RJ, editors. Brain Repair After Stroke. Cambridge, UK: Cambridge University Press; 2010:173-182.
45. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005;57:874-882.
46. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010;28:1099-1106.
47. Honmou O, Houkin K, Matsunaga T, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011;134:1790-1807.
48. Bhasin A, Srivastava MV, Kumaran SS, et al. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra 2011;1:93-104.
49. Cramer SC. Stratifying patients with stroke in trials that target brain repair. Stroke 2010;41:S114-S116.
50. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 2012;11:369-380.
51. Cramer SC, Procaccio V. Correlation between genetic polymorphisms and stroke recovery: analysis of the GAIN Americas and GAIN International Studies. Eur J Neurol 2012;19:718-724.
52. Cramer S. Clinical issues in animal models of stroke and rehabilitation. ILAR J 2003;44:83-84.
53. Institute of Medicine. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. Washington, DC: National Academies Press; 2013.
54. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110:3507-3512.
55. Devine S. Mesenchymal stem cells: will they have a role in the clinic? J Cell Biochem Suppl 2002;38:73-79.
56. Hilfiker A, Kasper C, Hass R, Haverich A. Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation? Langenbecks Arch Surg 2011;396: 489-497.
57. Bhasin A, Srivastava MV, Mohanty S, Bhatia R, Kumaran SS, Bose S. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg 2013;115:1003-1008.